New hope for itchy eyelids? drug trial targets stubborn rash
NCT ID NCT06684522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a pill called upadacitinib for people with eyelid dermatitis that hasn't gotten better with standard creams. Ten adults aged 18-70 will take the drug for 12 weeks to see if it reduces redness and irritation. The goal is to find a new option for those who haven't had success with other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYELID DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University Department of Dermatology
RECRUITINGChicago, Illinois, 60611, United States